Dysregulation of TGFβ1 activity in cancer and its influence on the quality of anti-tumor immunity

Journal of Clinical Medicine

Volumn 5, Issue 9, 2016, Pages

  Hargadon, Kristian M ^a  

^a HAMPDEN SYDNEY COLLEGE   (United States)

Author keywords

Cancer; Dendritic cell; Immune suppression; Immunotherapy; T cell; TGF 1

Indexed keywords

ARGINASE 1; CD4 ANTIGEN; CD8 ANTIGEN; CXCL1 CHEMOKINE; FRESOLIMUMAB; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 10; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MODAFINIL; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; RAS PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; COLORECTAL CARCINOMA; DENDRITIC CELL; EPITHELIAL MESENCHYMAL TRANSITION; EWING SARCOMA; GENE OVEREXPRESSION; HUMAN; IMMUNOREGULATION; LIVER CANCER; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEOPLASM; NEUTROPHIL CHEMOTAXIS; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; THYROID CANCER; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 85021768050     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5090076     Document Type: Review

References (163)

1. Massagué, J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 2000, 1, 169-178. [CrossRef] [PubMed]
2. Gordon, K.J.; Blobe, G.C. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta 2008, 1782, 197-228. [CrossRef] [PubMed]
3. Qi, W.; Gao, S.; Wang, Z. Transcriptional regulation of the TGF-beta1 promoter by androgen receptor. Biochem. J. 2008, 416, 453-462. [CrossRef] [PubMed]
4. Sullivan, D.E.; Ferris, M.; Nguyen, H.; Abboud, E.; Brody, A.R. TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J. Cell. Mol. Med. 2009, 13, 1866-1876. [CrossRef] [PubMed]
5. Fraser, D.; Brunskill, N.; Ito, T.; Phillips, A. Long-term exposure of proximal tubular epithelial cells to glucose induces transforming growth factor-beta 1 synthesis via an autocrine PDGF loop. Am. J. Pathol. 2003, 163, 2565-2574. [CrossRef] [PubMed]
6. Bascom, C.C.; Wolfshohl, J.R.; Coffey, R.J.; Madisen, L.; Webb, N.R.; Purchio, A.R.; Derynck, R.; Moses, H.L. Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Mol. Cell. Biol. 1989, 9, 5508-5515. [CrossRef] [PubMed]
7. Xiao, Y.Q.; Freire-de-Lima, C.G.; Schiemann, W.P.; Bratton, D.L.; Vandivier, R.W.; Henson, P.M. Transcriptional and translational regulation of TGF-beta production in response to apoptotic cells. J. Immunol.2008, 181, 3575-3585. [CrossRef] [PubMed]
8. Chegini, N.; Tang, X.M.; Ma, C. Regulation of transforming growth factor-beta1 expression by granulocyte macrophage-colony-stimulating factor in leiomyoma and myometrial smooth muscle cells. J. Clin. Endocrinol. Metab. 1999, 84, 4138-4143. [PubMed]
9. Grewal, J.S.; Mukhin, Y.V.; Garnovskaya, M.N.; Raymond, J.R.; Greene, E.L. Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: Proliferative and fibrotic signals. Am. J. Physiol.1999, 276, F922-F930. [PubMed]
10. Li, Z.-D.; Bork, J.P.; Krueger, B.; Patsenker, E.; Schulze-Krebs, A.; Hahn, E.G.; Schuppan, D. VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem. Biophys. Res. Commun. 2005, 334, 1049-1060. [CrossRef] [PubMed]
11. Yue, J.; Mulder, K.M. Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. J. Biol. Chem. 2000, 275, 30765-30773. [CrossRef] [PubMed]
12. Birchenall-Roberts, M.C.; Ruscetti, F.W.; Kasper, J.; Lee, H.D.; Friedman, R.; Geiser, A.; Sporn, M.B.; Roberts, A.B.; Kim, S.J. Transcriptional regulation of the transforming growth factor beta 1 promoter by v-src gene products is mediated through the AP-1 complex. Mol. Cell. Biol. 1990, 10, 4978-4983. [CrossRef] [PubMed]
13. Lee, K.-Y.; Ito, K.; Hayashi, R.; Jazrawi, E.P.I.; Barnes, P.J.; Adcock, I.M. NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. J. Immunol. 2006, 176, 603-615. [CrossRef] [PubMed]
14. Geiser, A.G.; Busam, K.J.; Kim, S.J.; Lafyatis, R.; O’Reilly, M.A.; Webbink, R.; Roberts, A.B.; Sporn, M.B. Regulation of the transforming growth factor-beta 1 and -beta 3 promoters by transcription factor Sp1. Gene 1993, 129, 223-228. [CrossRef] [PubMed]
15. Kim, S.; Glick, A.; Sporn, M.; Roberts, A. Characterization of the promoter region of the human transforming growth factor-beta 1 gene. J. Biol. Chem. 1989, 264, 402-408. [PubMed]
16. Kinjyo, I.; Inoue, H.; Hamano, S.; Fukuyama, S.; Yoshimura, T.; Koga, K.; Takaki, H.; Himeno, K.; Takaesu, G.; Kobayashi, T.; et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J. Exp. Med. 2006, 203, 1021-1031. [CrossRef] [PubMed]
17. Kubiczkova, L.; Sedlarikova, L.; Hajek, R.; Sevcikova, S. TGF-β-An excellent servant but a bad master. J. Transl. Med. 2012, 10, 183. [CrossRef] [PubMed]
18. Massagué, J.; Seoane, J.;Wotton, D. Smad transcription factors. Genes Dev. 2005, 19, 2783-2810. [CrossRef] [PubMed]
19. Papageorgis, P.; Lambert, A.W.; Ozturk, S.; Gao, F.; Pan, H.; Manne, U.; Alekseyev, Y.O.; Thiagalingam, A.; Abdolmaleky, H.M.; Lenburg, M.; et al. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res. 2010, 70, 968-978. [CrossRef] [PubMed]
20. Ross, S.; Cheung, E.; Petrakis, T.G.; Howell, M.; Kraus,W.L.; Hill, C.S. Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription. EMBO J. 2006, 25, 4490-4502. [CrossRef] [PubMed]
21. Xi, Q.; Wang, Z.; Zaromytidou, A.-I.; Zhang, X.H.-F.; Chow-Tsang, L.-F.; Liu, J.X.; Kim, H.; Barlas, A.; Manova-Todorova, K.; Kaartinen, V.; et al. A poised chromatin platform for TGF-β access to master regulators. Cell 2011, 147, 1511-1524. [CrossRef] [PubMed]
22. Chaudhury, A.; Howe, P.H. The tale of transforming growth factor-beta (TGFbeta) signaling: A soigné enigma. IUBMB Life 2009, 61, 929-939. [CrossRef] [PubMed]
23. Papageorgis, P. TGFβ signaling in tumor initiation, epithelial-to-mesenchymal transition, and metastasis. J. Oncol. 2015, 2015, 587193. [CrossRef] [PubMed]
24. Tucker, R.F.; Shipley, G.D.; Moses, H.L.; Holley, R.W. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 1984, 226, 705-707. [CrossRef] [PubMed]
25. Ristow, H.J. BSC-1 growth inhibitor/type beta transforming growth factor is a strong inhibitor of thymocyte proliferation. Proc. Natl. Acad. Sci. USA 1986, 83, 5531-5533. [CrossRef] [PubMed]
26. Fernandez-Pol, J.A.; Talkad, V.D.; Klos, D.J.; Hamilton, P.D. Suppression of the EGF-dependent induction of c-myc proto-oncogene expression by transforming growth factor beta in a human breast carcinoma cell line. Biochem. Biophys. Res. Commun. 1987, 144, 1197-1205. [CrossRef] [PubMed]
27. Pietenpol, J.A.; Holt, J.T.; Stein, R.W.; Moses, H.L. Transforming growth factor beta 1 suppression of c-myc gene transcription: Role in inhibition of keratinocyte proliferation. Proc. Natl. Acad. Sci. USA 1990, 87, 3758-3762. [CrossRef] [PubMed]
28. Hannon, G.J.; Beach, D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994, 371, 257-261. [CrossRef] [PubMed]
29. Datto, M.B.; Li, Y.; Panus, J.F.; Howe, D.J.; Xiong, Y.; Wang, X.F. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 1995, 92, 5545-5549. [CrossRef] [PubMed]
30. Polyak, K.; Kato, J.Y.; Solomon, M.J.; Sherr, C.J.; Massague, J.; Roberts, J.M.; Koff, A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994, 8, 9-22. [CrossRef] [PubMed]
31. Pillaire, M.J.; Casagrande, F.; Malecaze, F.; Manenti, S.; Darbon, J.M. Regulation by transforming growth factor-beta 1 of G1 cyclin-dependent kinases in human retinal epithelial cells. Exp. Eye Res. 1999, 68, 193-199. [CrossRef] [PubMed]
32. Djaborkhel, R.; Tvrdík, D.; Eckschlager, T.; Raska, I.; Müller, J. Cyclin A down-regulation in TGFbeta1-arrested follicular lymphoma cells. Exp. Cell Res. 2000, 261, 250-259. [CrossRef] [PubMed]
33. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2, 401-404. [CrossRef] [PubMed]
34. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6, pl1. [CrossRef] [PubMed]
35. Krasagakis, K.; Thölke, D.; Farthmann, B.; Eberle, J.; Mansmann, U.; Orfanos, C.E. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br. J. Cancer 1998, 77, 1492-1494. [CrossRef] [PubMed]
36. Kong, F.M.; Anscher, M.S.; Murase, T.; Abbott, B.D.; Iglehart, J.D.; Jirtle, R.L. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg.1995, 222, 155-162. [CrossRef] [PubMed]
37. Ivanović, V.; Demajo, M.; Krtolica, K.; Krajnović, M.; Konstantinović, M.; Baltić, V.; Prtenjak, G.; Stojiljković, B.; Breberina, M.; Nesković-Konstantinović, Z.; et al. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin. Chim. Acta. 2006, 371, 191-193. [CrossRef] [PubMed]
38. Friess, H.; Yamanaka, Y.; Büchler, M.; Ebert, M.; Beger, H.G.; Gold, L.I.; Korc, M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993, 105, 1846-1856. [CrossRef] [PubMed]
39. Mitropoulos, D.; Kiroudi, A.; Christelli, E.; Serafetinidis, E.; Zervas, A.; Anastasiou, I.; Dimopoulos, C. Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol. Res. 2004, 32, 317-322. [CrossRef] [PubMed]
40. Xiong, B.; Gong, L.-L.; Zhang, F.; Hu, M.-B.; Yuan, H.-Y. TGF beta1 expression and angiogenesis in colorectal cancer tissue. World J. Gastroenterol. 2002, 8, 496-498. [CrossRef] [PubMed]
41. Chen, Y.; Ma, L.; He, Q.; Zhang, S.; Zhang, C.; Jia, W. TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. Biol. Res. 2015, 48, 26. [CrossRef] [PubMed]
42. Wu, Y.-C.; Tang, S.-J.; Sun, G.-H.; Sun, K.-H. CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer. Oncogene 2015, 35, 2123-2132. [CrossRef] [PubMed]
43. Kim, J.-W.; Koh, Y.; Kim, D.-W.; Ahn, Y.-O.; Kim, T.M.; Han, S.-W.; Oh, D.-Y.; Lee, S.-H.; Im, S.-A.; Kim, T.-Y.; et al. Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer. Cancer Res. Treat. 2013, 45, 325-333. [CrossRef] [PubMed]
44. Zhuang, J.; Lu, Q.; Shen, B.; Huang, X.; Shen, L.; Zheng, X.; Huang, R.; Yan, J.; Guo, H. TGFβ1 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT. Sci. Rep. 2015, 5, 11924. [CrossRef] [PubMed]
45. Terabe, M.; Matsui, S.; Park, J.-M.; Mamura, M.; Noben-Trauth, N.; Donaldson, D.D.; Chen,W.;Wahl, S.M.; Ledbetter, S.; Pratt, B.; et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J. Exp. Med. 2003, 198, 1741-1752. [CrossRef] [PubMed]
46. Ghiringhelli, F.; Puig, P.E.; Roux, S.; Parcellier, A.; Schmitt, E.; Solary, E.; Kroemer, G.; Martin, F.; Chauffert, B.; Zitvogel, L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 2005, 202, 919-929. [CrossRef] [PubMed]
47. Dumitriu, I.E.; Dunbar, D.R.; Howie, S.E.; Sethi, T.; Gregory, C.D. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 2009, 182, 2795-2807. [CrossRef] [PubMed]
48. Kadin, M.E.; Cavaille-Coll, M.W.; Gertz, R.; Massagué, J.; Cheifetz, S.; George, D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc. Natl. Acad. Sci. USA 1994, 91, 6002-6006. [CrossRef] [PubMed]
49. Markowitz, S.; Wang, J.; Myeroff, L.; Parsons, R.; Sun, L.; Lutterbaugh, J.; Fan, R.S.; Zborowska, E.; Kinzler, K.W.; Vogelstein, B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268, 1336-1338. [CrossRef] [PubMed]
50. Garrigue-Antar, L.; Muñoz-Antonia, T.; Antonia, S.J.; Gesmonde, J.; Vellucci, V.F.; Reiss, M. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res. 1995, 55, 3982-3987. [PubMed]
51. Guo, Y.; Jacobs, S.C.; Kyprianou, N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int. J. Cancer 1997, 71, 573-579. [CrossRef] [PubMed]
52. Kim, I.Y.; Ahn, H.J.; Zelner, D.J.; Shaw, J.W.; Lang, S.; Kato, M.; Oefelein, M.G.; Miyazono, K.; Nemeth, J.A.; Kozlowski, J.M.; et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res. 1996, 2, 1255-1261. [PubMed]
53. Lu, S.-L.; Herrington, H.; Reh, D.; Weber, S.; Bornstein, S.; Wang, D.; Li, A.G.; Tang, C.-F.; Siddiqui, Y.; Nord, J.; et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 2006, 20, 1331-1342. [CrossRef] [PubMed]
54. Schutte, M.; Hruban, R.H.; Hedrick, L.; Cho, K.R.; Nadasdy, G.M.; Weinstein, C.L.; Bova, G.S.; Isaacs, W.B.; Cairns, P.; Nawroz, H.; et al. DPC4 gene in various tumor types. Cancer Res. 1996, 56, 2527-2530. [PubMed]
55. Hahn, S.A.; Hoque, A.T.; Moskaluk, C.A.; da Costa, L.T.; Schutte, M.; Rozenblum, E.; Seymour, A.B.; Weinstein, C.L.; Yeo, C.J.; Hruban, R.H.; et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996, 56, 490-494. [PubMed]
56. Eppert, K.; Scherer, S.W.; Ozcelik, H.; Pirone, R.; Hoodless, P.; Kim, H.; Tsui, L.C.; Bapat, B.; Gallinger, S.; Andrulis, I.L.; et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996, 86, 543-552. [CrossRef] [PubMed]
57. Sjöblom, T.; Jones, S.; Wood, L.D.; Parsons, D.W.; Lin, J.; Barber, T.D.; Mandelker, D.; Leary, R.J.; Ptak, J.; Silliman, N.; et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268-274. [CrossRef] [PubMed]
58. Kretzschmar, M.; Doody, J.; Timokhina, I.; Massagué, J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 1999, 13, 804-816. [CrossRef] [PubMed]
59. Kretzschmar, M.; Doody, J.; Massagué, J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997, 389, 618-622. [PubMed]
60. Kleeff, J.; Ishiwata, T.; Maruyama, H.; Friess, H.; Truong, P.; Büchler, M.W.; Falb, D.; Korc, M. The TGF-beta signaling inhibitor Smad 7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999, 18, 5363-5372. [CrossRef] [PubMed]
61. Dowdy, S.C.; Mariani, A.; Reinholz, M.M.; Keeney, G.L.; Spelsberg, T.C.; Podratz, K.C.; Janknecht, R. Overexpression of the TGF-beta antagonist Smad 7 in endometrial cancer. Gynecol. Oncol. 2005, 96, 368-373. [CrossRef] [PubMed]
62. Ranganathan, P.; Agrawal, A.; Bhushan, R.; Chavalmane, A.K.; Kalathur, R.; Takahashi, T.; Kondaiah, P. Expression profiling of genes regulated by TGF-beta: Differential regulation in normal and tumour cells. BMC Genom. 2007, 8, 98. [CrossRef] [PubMed]
63. Lebrun, J.-J.; Lebrun, J.-J. The dual role of TGFβ in human cancer: From tumor suppression to cancer metastasis. ISRN Mol. Biol. 2012, 2012, 1-28. [CrossRef] [PubMed]
64. Albert, M.L.; Jegathesan, M.; Darnell, R.B. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat. Immunol. 2001, 2, 1010-1017. [CrossRef] [PubMed]
65. Hawiger, D.; Inaba, K.; Dorsett, Y.; Guo, M.; Mahnke, K.; Rivera, M.; Ravetch, J.V.; Steinman, R.M.; Nussenzweig, M.C. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001, 194, 769-780. [CrossRef] [PubMed]
66. Dhodapkar, M.V.; Steinman, R.M.; Krasovsky, J.; Munz, C.; Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 2001, 193, 233-238. [CrossRef] [PubMed]
67. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12, 991-1045. [CrossRef] [PubMed]
68. Joffre, O.; Nolte, M.A.; Spörri, R.; Reis e Sousa, C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 2009, 227, 234-247. [CrossRef] [PubMed]
69. Yamaguchi, Y.; Tsumura, H.; Miwa, M.; Inaba, K. Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 1997, 15, 144-153. [CrossRef] [PubMed]
70. Wang, S.; Yang, J.; Qian, J.;Wezeman, M.; Kwak, L.W.; Yi, Q. Tumor evasion of the immune system: Inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006, 107, 2432-2439. [CrossRef] [PubMed]
71. Oosterhoff, D.; Lougheed, S.; van de Ven, R.; Lindenberg, J.; van Cruijsen, H.; Hiddingh, L.; Kroon, J.; van den Eertwegh, A.J.M.; Hangalapura, B.; Scheper, R.J.; et al. Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology 2012, 1, 649-658. [CrossRef] [PubMed]
72. Xiang, X.; Poliakov, A.; Liu, C.; Liu, Y.; Deng, Z.; Wang, J.; Cheng, Z.; Shah, S.V.; Wang, G.-J.; Zhang, L.; et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 2009, 124, 2621-2633. [CrossRef] [PubMed]
73. Lechner, M.G.; Megiel, C.; Russell, S.M.; Bingham, B.; Arger, N.; Woo, T.; Epstein, A.L. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J. Transl. Med.2011, 9, 90. [CrossRef] [PubMed]
74. Marvel, D.; Gabrilovich, D.I. Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J. Clin. Investig. 2015, 125, 3356-3364. [CrossRef] [PubMed]
75. Ostrand-Rosenberg, S.; Sinha, P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol. 2009, 182, 4499-4506. [CrossRef] [PubMed]
76. Geissmann, F.; Revy, P.; Regnault, A.; Lepelletier, Y.; Dy, M.; Brousse, N.; Amigorena, S.; Hermine, O.; Durandy, A. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol.1999, 162, 4567-4575. [PubMed]
77. Laouar, Y.; Town, T.; Jeng, D.; Tran, E.; Wan, Y.; Kuchroo, V.K.; Flavell, R.A. TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2008, 105, 10865-10870. [CrossRef] [PubMed]
78. Ramalingam, R.; Larmonier, C.B.; Thurston, R.D.; Midura-Kiela, M.T.; Zheng, S.G.; Ghishan, F.K.; Kiela, P.R. Dendritic cell-specific disruption of TGF-β receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J. Immunol. 2012, 189, 3878-3893. [CrossRef] [PubMed]
79. Hargadon, K.M.; Bishop, J.D.; Brandt, J.P.; Hand, Z.C.; Ararso, Y.T.; Forrest, O.A. Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells. Immunol. Cell Biol. 2016, 94, 24-38. [CrossRef] [PubMed]
80. Belladonna, M.L.; Volpi, C.; Bianchi, R.; Vacca, C.; Orabona, C.; Pallotta, M.T.; Boon, L.; Gizzi, S.; Fioretti, M.C.; Grohmann, U.; et al. Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 2008, 181, 5194-5198. [CrossRef] [PubMed]
81. Hargadon, K.M. Tumor-altered dendritic cell function: Implications for anti-tumor immunity. Front. Immunol.2013, 4, 192. [CrossRef] [PubMed]
82. Scarlett, U.K.; Rutkowski, M.R.; Rauwerdink, A.M.; Fields, J.; Escovar-Fadul, X.; Baird, J.; Cubillos-Ruiz, J.R.; Jacobs, A.C.; Gonzalez, J.L.;Weaver, J.; et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 2012, 209, 495-506. [CrossRef] [PubMed]
83. Sisirak, V.; Faget, J.; Gobert, M.; Goutagny, N.; Vey, N.; Treilleux, I.; Renaudineau, S.; Poyet, G.; Labidi-Galy, S.I.; Goddard-Leon, S.; et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res. 2012, 72, 5188-5197. [CrossRef] [PubMed]
84. Sisirak, V.; Vey, N.; Goutagny, N.; Renaudineau, S.; Malfroy, M.; Thys, S.; Treilleux, I.; Labidi-Galy, S.I.; Bachelot, T.; Dezutter-Dambuyant, C.; et al. Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells. Int. J. Cancer 2013, 133, 771-778. [CrossRef] [PubMed]
85. Standiford, T.J.; Kuick, R.; Bhan, U.; Chen, J.; Newstead, M.; Keshamouni, V.G. TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 2011, 30, 2475-2484. [CrossRef] [PubMed]
86. Machado, C.M.L.; Andrade, L.N.S.; Teixeira, V.R.; Costa, F.F.; Melo, C.M.; dos Santos, S.N.; Nonogaki, S.; Liu, F.-T.; Bernardes, E.S.; Camargo, A.A.; et al. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from β1-induced macrophages. Cancer Med. 2014, 3, 201-214. [CrossRef] [PubMed]
87. Alleva, D.G.;Walker, T.M.; Elgert, K.D. Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: Contrasting effects on resting and activated macrophages. J. Leukoc. Biol.1995, 57, 919-928. [PubMed]
88. Cao, Q.; Wang, Y.; Zheng, D.; Sun, Y.; Wang, Y.; Lee, V.W.S.; Zheng, G.; Tan, T.K.; Ince, J.; Alexander, S.I.; et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J. Am. Soc. Nephrol. 2010, 21, 933-942. [CrossRef] [PubMed]
89. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pagès, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964. [CrossRef] [PubMed]
90. Steidl, C.; Lee, T.; Shah, S.P.; Farinha, P.; Han, G.; Nayar, T.; Delaney, A.; Jones, S.J.; Iqbal, J.; Weisenburger, D.D.; et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med. 2010, 362, 875-885. [CrossRef] [PubMed]
91. DeNardo, D.G.; Brennan, D.J.; Rexhepaj, E.; Ruffell, B.; Shiao, S.L.; Madden, S.F.; Gallagher, W.M.; Wadhwani, N.; Keil, S.D.; Junaid, S.A.; et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1, 54-67. [CrossRef] [PubMed]
92. Kurahara, H.; Shinchi, H.; Mataki, Y.; Maemura, K.; Noma, H.; Kubo, F.; Sakoda, M.; Ueno, S.; Natsugoe, S.; Takao, S. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 2011, 167, e211-e219. [CrossRef] [PubMed]
93. Zhang, B.C.; Gao, J.; Wang, J.; Rao, Z.G.; Wang, B.C.; Gao, J.F. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med. Oncol.2011, 28, 1447-1452. [CrossRef] [PubMed]
94. Fridlender, Z.G.; Sun, J.; Kim, S.; Kapoor, V.; Cheng, G.; Ling, L.; Worthen, G.S.; Albelda, S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16, 183-194. [CrossRef] [PubMed]
95. Sadot, E.; Basturk, O.; Klimstra, D.S.; Gönen, M.; Lokshin, A.; Do, R.K.G.; D’Angelica, M.I.; DeMatteo, R.P.; Kingham, T.P.; Jarnagin, W.R.; et al. Tumor-associated neutrophils and malignant progression in intraductal papillary mucinous neoplasms. Ann. Surg. 2015, 262, 1102-1107. [CrossRef] [PubMed]
96. Shen, M.; Hu, P.; Donskov, F.;Wang, G.; Liu, Q.; Du, J. Tumor-associated neutrophils as a new prognostic factor in cancer: A systematic review and meta-analysis. PLoS ONE 2014, 9, 646-674. [CrossRef] [PubMed]
97. Fan, Q.-M.; Jing, Y.-Y.; Yu, G.-F.; Kou, X.-R.; Ye, F.; Gao, L.; Li, R.; Zhao, Q.-D.; Yang, Y.; Lu, Z.-H.; et al. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett. 2014, 352, 160-168. [CrossRef] [PubMed]
98. Tham, M.; Tan, K.W.; Keeble, J.; Wang, X.; Hubert, S.; Barron, L.; Tan, N.S.; Kato, M.; Prevost-Blondel, A.; Angeli, V.; et al. Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation. Oncotarget 2014, 5, 12027-12042. [CrossRef] [PubMed]
99. Shankaran, V.; Ikeda, H.; Bruce, A.T.; White, J.M.; Swanson, P.E.; Old, L.J.; Schreiber, R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410, 1107-1111. [CrossRef] [PubMed]
100. Van den Broek, M.E.; Kägi, D.; Ossendorp, F.; Toes, R.; Vamvakas, S.; Lutz, W.K.; Melief, C.J.; Zinkernagel, R.M.; Hengartner, H. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med.1996, 184, 1781-1790. [CrossRef] [PubMed]
101. Smyth, M.J.; Thia, K.Y.; Street, S.E.; MacGregor, D.; Godfrey, D.I.; Trapani, J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 2000, 192, 755-760. [CrossRef] [PubMed]
102. Penn, I. Tumors of the immunocompromised patient. Annu. Rev. Med. 1988, 39, 63-73. [CrossRef] [PubMed]
103. Dantal, J.; Soulillou, J.-P. Immunosuppressive drugs and the risk of cancer after organ transplantation. N. Engl. J. Med. 2009, 353, 1371-1373. [CrossRef] [PubMed]
104. Halliday, G.M.; Patel, A.; Hunt, M.J.; Tefany, F.J.; Barnetson, R.S.C. Spontaneous regression of human melanoma/nonmelanoma skin cancer: Association with infiltrating CD4+ T cells. World J. Surg. 1995, 19, 352-358. [CrossRef] [PubMed]
105. Yamshchikov, G.; Thompson, L.; Ross,W.G.; Galavotti, H.; Aquila,W.; Deacon, D.; Caldwell, J.; Patterson, J.W.; Hunt, D.F.; Slingluff, C.L. Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations. Clin. Cancer Res. 2001, 7, 909s-916s. [PubMed]
106. Anichini, A.; Scarito, A.; Molla, A.; Parmiani, G.; Mortarini, R. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: Role of common gamma-chain cytokines. J. Immunol. 2003, 171, 2134-2141. [CrossRef] [PubMed]
107. Zippelius, A.; Batard, P.; Rubio-godoy, V.; Bioley, G.; Lie, D.; Lejeune, F.; Rimoldi, D.; Guillaume, P.; Meidenbauer, N.; Mackensen, A.; et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res. 2004, 64, 2865-2873. [CrossRef] [PubMed]
108. Mortarini, R.; Piris, A.; Maurichi, A.; Molla, A.; Bersani, I.; Bono, A.; Bartoli, C.; Santinami, M.; Lombardo, C.; Ravagnani, F.; et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 2003, 63, 2535-2545. [PubMed]
109. Fourcade, J.; Sun, Z.; Benallaoua, M.; Guillaume, P.; Luescher, I.F.; Sander, C.; Kirkwood, J.M.; Kuchroo, V.; Zarour, H.M. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010, 207, 2175-2186. [CrossRef] [PubMed]
110. Fu, J.; Xu, D.; Liu, Z.; Shi, M.; Zhao, P.; Fu, B.; Zhang, Z.; Yang, H.; Zhang, H.; Zhou, C.; et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132, 2328-2339. [CrossRef] [PubMed]
111. Li, M.O.; Sanjabi, S.; Flavell, R.A. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006, 25, 455-471. [CrossRef] [PubMed]
112. Marie, J.C.; Liggitt, D.; Rudensky, A.Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor. Immunity 2006, 25, 441-454. [CrossRef] [PubMed]
113. Chou, C.K.; Schietinger, A.; Liggitt, H.D.; Tan, X.; Funk, S.; Freeman, G.J.; Ratliff, T.L.; Greenberg, N.M.; Greenberg, P.D. Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J. Immunol. 2012, 189, 3936-3946. [CrossRef] [PubMed]
114. Xie, Y.; Bai, O.; Yuan, J.; Chibbar, R.; Slattery, K.;Wei, Y.; Deng, Y.; Xiang, J. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses. Cancer Res. 2009, 69, 7756-7766. [CrossRef] [PubMed]
115. Shvedova, A.A.; Kisin, E.R.; Yanamala, N.; Tkach, A.V.; Gutkin, D.W.; Star, A.; Shurin, G.V.; Kagan, V.E.; Shurin, M.R. MDSC and TGFβ are required for facilitation of tumor growth in the lungs of mice exposed to carbon nanotubes. Cancer Res. 2015, 75, 1615-1623. [CrossRef] [PubMed]
116. Chen, W.; Jin, W.; Hardegen, N.; Lei, K.-J.; Li, L.; Marinos, N.; McGrady, G.; Wahl, S.M. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 2003, 198, 1875-1886. [CrossRef] [PubMed]
117. Patel, S.A.; Meyer, J.R.; Greco, S.J.; Corcoran, K.E.; Bryan, M.; Rameshwar, P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-beta. J. Immunol.2010, 184, 5885-5894. [CrossRef] [PubMed]
118. Huang, B.; Pan, P.-Y.; Li, Q.; Sato, A.I.; Levy, D.E.; Bromberg, J.; Divino, C.M.; Chen, S.-H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66, 1123-1131. [CrossRef] [PubMed]
119. Shurin, G.V.; Ma, Y.; Shurin, M.R. Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron. 2013, 6, 159-167. [CrossRef] [PubMed]
120. Nakamura, K.; Kitani, A.; Strober, W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 2001, 194, 629-644. [CrossRef] [PubMed]
121. Chen, M.-L.; Pittet, M.J.; Gorelik, L.; Flavell, R.A.; Weissleder, R.; von Boehmer, H.; Khazaie, K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. USA 2005, 102, 419-424. [CrossRef] [PubMed]
122. De Jong, E.; Suddason, T.; Lord, G.M. Translational mini-review series on Th17 cells: Development of mouse and human T helper 17 cells. Clin. Exp. Immunol. 2010, 159, 148-158. [CrossRef] [PubMed]
123. Zou,W.; Restifo, N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 2010, 10, 248-256. [CrossRef] [PubMed]
124. Wang, L.; Yi, T.; Kortylewski, M.; Pardoll, D.M.; Zeng, D.; Yu, H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009, 206, 1457-1464. [CrossRef] [PubMed]
125. He, D.; Li, H.; Yusuf, N.; Elmets, C.A.; Li, J.; Mountz, J.D.; Xu, H. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J. Immunol. 2010, 184, 2281-2288. [CrossRef] [PubMed]
126. De Simone, V.; Franzè, E.; Ronchetti, G.; Colantoni, A.; Fantini, M.C.; di Fusco, D.; Sica, G.S.; Sileri, P.; MacDonald, T.T.; Pallone, F.; et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-κB to promote colorectal cancer cell growth. Oncogene 2015, 34, 3493-3503. [CrossRef] [PubMed]
127. Prabhala, R.H.; Pelluru, D.; Fulciniti, M.; Prabhala, H.K.; Nanjappa, P.; Song, W.; Pai, C.; Amin, S.; Tai, Y.-T.; Richardson, P.G.; et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010, 115, 5385-5392. [CrossRef] [PubMed]
128. Iida, T.; Iwahashi, M.; Katsuda, M.; Ishida, K.; Nakamori, M.; Nakamura, M.; Naka, T.; Ojima, T.; Ueda, K.; Hayata, K.; et al. Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol. Rep. 2011, 25, 1271-1277. [PubMed]
129. Zhang, J.-P.; Yan, J.; Xu, J.; Pang, X.-H.; Chen, M.-S.; Li, L.; Wu, C.; Li, S.-P.; Zheng, L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 2009, 50, 980-989. [CrossRef] [PubMed]
130. Waldhauer, I.; Steinle, A. NK cells and cancer immunosurveillance. Oncogene 2008, 27, 5932-5943. [CrossRef] [PubMed]
131. Li, H.; Han, Y.; Guo, Q.; Zhang, M.; Cao, X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 2009, 182, 240-249. [CrossRef] [PubMed]
132. Sui, Q.; Zhang, J.; Sun, X.; Zhang, C.; Han, Q.; Tian, Z. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma. J. Immunol. 2014, 193, 2016-2023. [CrossRef] [PubMed]
133. Dasgupta, S.; Bhattacharya-Chatterjee, M.; O’Malley, B.W.; Chatterjee, S.K. Inhibition of NK cell activity through TGF-1 by down-regulation of NKG2D in a murine model of head and neck cancer. J. Immunol. 2005, 175, 5541-5550. [CrossRef] [PubMed]
134. Donatelli, S.S.; Zhou, J.-M.; Gilvary, D.L.; Eksioglu, E.A.; Chen, X.; Cress,W.D.; Haura, E.B.; Schabath, M.B.; Coppola, D.; Wei, S.; et al. TGF-inducible microRNA-183 silences tumor-associated natural killer cells. Proc. Natl. Acad. Sci. USA 2014, 111, 4203-4208. [CrossRef] [PubMed]
135. Viel, S.; Marçais, A.; Guimaraes, F.S.-F.; Loftus, R.; Rabilloud, J.; Grau, M.; Degouve, S.; Djebali, S.; Sanlaville, A.; Charrier, E.; et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 2016, 9. [CrossRef] [PubMed]
136. Lee, J.-C.; Lee, K.-M.; Kim, D.-W.; Heo, D.S. Elevated TGF-1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 2004, 172, 7335-7340. [CrossRef] [PubMed]
137. Yoon, S.J.; Heo, D.S.; Kang, S.H.; Lee, K.H.; Kim,W.S.; Kim, G.P.; Lee, J.A.; Lee, K.S.; Bang, Y.J.; Kim, N.K. Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-beta 1 expression. Anticancer Res. 1997, 18, 1591-1596.
138. Kim, S.; Buchlis, G.; Fridlender, Z.G.; Sun, J.; Kapoor, V.; Cheng, G.; Haas, A.; Cheung, H.K.; Zhang, X.; Corbley, M.; et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res. 2008, 68, 10247-10256. [CrossRef] [PubMed]
139. Suzuki, E.; Kapoor, V.; Cheung, H.K.; Ling, L.E.; DeLong, P.A.; Kaiser, L.R.; Albelda, S.M. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin. Cancer Res. 2004, 10, 5907-5918. [CrossRef] [PubMed]
140. Takaku, S.; Terabe, M.; Ambrosino, E.; Peng, J.; Lonning, S.; McPherson, J.M.; Berzofsky, J.A. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int. J. Cancer 2010, 126, 1666-1674. [PubMed]
141. Penafuerte, C.; Bautista-Lopez, N.; Bouchentouf, M.; Birman, E.; Forner, K.; Galipeau, J. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J. Immunol. 2011, 186, 6933-6944. [CrossRef] [PubMed]
142. Conroy, H.; Galvin, K.C.; Higgins, S.C.; Mills, K.H.G. Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells. Cancer Immunol. Immunother. 2012, 61, 425-431. [CrossRef] [PubMed]
143. Sakuraba, H.; Ishiguro, Y.; Yamagata, K.; Munakata, A.; Nakane, A. Blockade of TGF-β accelerates mucosal destruction through epithelial cell apoptosis. Biochem. Biophys. Res. Commun. 2007, 359, 406-412. [CrossRef] [PubMed]
144. Rodrigues-Díez, R.; Rayego-Mateos, S.; Orejudo, M.; Aroeira, L.S.; Selgas, R.; Ortiz, A.; Egido, J.; Ruiz-Ortega, M. TGF-beta blockade increases renal inflammation caused by the C-terminal module of the CCN2. Mediat. Inflamm. 2015, 2015, 506041. [CrossRef] [PubMed]
145. Lacouture, M.E.; Morris, J.C.; Lawrence, D.P.; Tan, A.R.; Olencki, T.E.; Shapiro, G.I.; Dezube, B.J.; Berzofsky, J.A.; Hsu, F.J.; Guitart, J. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol. Immunother. 2015, 64, 437-446. [CrossRef] [PubMed]
146. Zhang, Q.; Yang, X.J.; Kundu, S.D.; Pins, M.; Javonovic, B.; Meyer, R.; Kim, S.-J.; Greenberg, N.M.; Kuzel, T.; Meagher, R.; et al. Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol. Cancer Ther. 2006, 5, 1733-1743. [CrossRef] [PubMed]
147. Zhang, Q.; Yang, X.; Pins, M.; Javonovic, B.; Kuzel, T.; Kim, S.-J.; van Parijs, L.; Greenberg, N.M.; Liu, V.; Guo, Y.; et al. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: Eradication of autologous mouse prostate cancer. Cancer Res. 2005, 65, 1761-1769. [CrossRef] [PubMed]
148. Zhang, Q.; Jang, T.L.; Yang, X.; Park, I.; Meyer, R.E.; Kundu, S.; Pins, M.; Javonovic, B.; Kuzel, T.; Kim, S.-J.; et al. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate 2006, 66, 235-247. [CrossRef] [PubMed]
149. Gate, D.; Danielpour, M.; Rodriguez, J.; Kim, G.-B.; Levy, R.; Bannykh, S.; Breunig, J.J.; Kaech, S.M.; Flavell, R.A.; Town, T. T-cell TGF-β signaling abrogation restricts medulloblastoma progression. Proc. Natl. Acad. Sci. USA 2014, 111, E3458-E3466. [CrossRef] [PubMed]
150. Zhang, L.; Yu, Z.; Muranski, P.; Palmer, D.C.; Restifo, N.P.; Rosenberg, S.A.; Morgan, R.A. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 2013, 20, 575-580. [CrossRef] [PubMed]
151. Foster, A.E.; Dotti, G.; Lu, A.; Khalil, M.; Brenner, M.K.; Heslop, H.E.; Rooney, C.M.; Bollard, C.M. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J. Immunother.2008, 31, 500-505. [CrossRef] [PubMed]
152. Lacuesta, K.; Buza, E.; Hauser, H.; Granville, L.; Pule, M.; Corboy, G.; Finegold, M.; Weiss, H.; Chen, S.Y.; Brenner, M.K.; et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J. Immunother. 2006, 29, 250-260. [CrossRef] [PubMed]
153. Wang, F.-L.; Qin, W.-J.; Wen, W.-H.; Tian, F.; Song, B.; Zhang, Q.; Lee, C.; Zhong, W.; Guo, Y.-L.; Wang, H. TGF-beta insensitive dendritic cells: An efficient vaccine for murine prostate cancer. Cancer Immunol. Immunother. 2007, 56, 1785-1793. [CrossRef] [PubMed]
154. Tian, F.;Wang, L.; Qin,W.;Wang, F.; Song, B.; Li, Y.;Wen,W.; Zhang, Z.; Zhu, K.; Zhang, Q.; et al. Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice. Cancer Lett. 2008, 271, 333-341. [CrossRef] [PubMed]
155. Ahn, Y.-H.; Hong, S.-O.; Kim, J.H.; Noh, K.H.; Song, K.-H.; Lee, Y.-H.; Jeon, J.-H.; Kim, D.-W.; Seo, J.H.; Kim, T.W. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. Clin. Exp. Immunol. 2015, 181, 164-178. [CrossRef] [PubMed]
156. Cubillos-Ruiz, J.R.; Baird, J.R.; Tesone, A.J.; Rutkowski, M.R.; Scarlett, U.K.; Camposeco-Jacobs, A.L.; Anadon-Arnillas, J.; Harwood, N.M.; Korc, M.; Fiering, S.N.; et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res. 2012, 72, 1683-1693. [CrossRef] [PubMed]
157. Neuzillet, C.; Tijeras-Raballand, A.; Cohen, R.; Cros, J.; Faivre, S.; Raymond, E.; de Gramont, A. Targeting the TGFβ pathway for cancer therapy. Pharmacol. Ther. 2015, 147, 22-31. [CrossRef] [PubMed]
158. Stevenson, J.P.; Kindler, H.L.; Papasavvas, E.; Sun, J.; Jacobs-Small, M.; Hull, J.; Schwed, D.; Ranganathan, A.; Newick, K.; Heitjan, D.F.; et al. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2013, 2, e26218. [CrossRef] [PubMed]
159. Senzer, N.; Barve, M.; Kuhn, J.; Melnyk, A.; Beitsch, P.; Lazar, M.; Lifshitz, S.; Magee, M.; Oh, J.; Mill, S.W.; et al. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell " vaccine (FANG) in advanced cancer. Mol. Ther. 2012, 20, 679-686. [PubMed]
160. Senzer, N.; Barve, M.; Nemunaitis, J.; Kuhn, J.; Melnyk, A.; Beltsch, P.; Magee, M.; Oh, J.; Bedell, C.; Kumar, P.; et al. Long term follow up: Phase I trial of "bi-shRNA furin/GMCSF DNA/Autologous tumor cell" immunotherapy (FANG™) in advanced cancer. J. Vaccines Vaccin. 2013, 4, 8.
161. Nemunaitis, J.; Barve, M.; Orr, D.; Kuhn, J.; Magee, M.; Lamont, J.; Bedell, C.;Wallraven, G.; Pappen, B.O.; Roth, A.; et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver. Oncology 2014, 87, 21-29. [CrossRef] [PubMed]
162. Ghisoli, M.; Barve, M.; Schneider, R.; Mennel, R.; Lenarsky, C.; Wallraven, G.; Pappen, B.O.; LaNoue, J.; Kumar, P.; Nemunaitis, D.; et al. Pilot trial of FANG immunotherapy in ewing’s sarcoma. Mol. Ther. 2015, 23, 1103-1109. [CrossRef] [PubMed]
163. Ghisoli, M.; Barve, M.; Mennel, R.; Lenarsky, C.; Horvath, S.; Wallraven, G.; Pappen, B.O.; Whiting, S.; Rao, D.; Senzer, N.; et al. Three year follow up of GMCSF/bi-shRNA(furin) DNA transfected autologous tumor immunotherapy (Vigil(™)) in metastatic advanced ewing’s sarcoma. Mol. Ther. 2016. [CrossRef] [PubMed]